alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
SCPW-22-0000223

IN THE SUPREME COURT OF THE STATE OF HAWAI # I

MICHAEL “ARLO” PAVICH, Petitioner

vs. S. WEAD, Warden of Saguaro Correctional Center; and DEPARTMENT OF PUBLIC SAFETY, STATE OF HAWAI # I , Respondents.

ORIGINAL PROCEEDING (Case No. 2PC011000015)

ORDER DENYING PETITION FOR WRIT OF HABEAS CORPUS (By: Nakayama, McKenna, Wilson, and Eddins, JJ., and Circuit Judge Castagnetti, in place of Recktenwald, C.J., recused) Upon consideration of the petition for writ of habeas corpus, filed on March 31, 2022, petitioner presents no special reason for invoking the supreme court’s original jurisdiction. See Oili v. Chang, 57 Haw. 411, 412, 557 P.2d 787, 788 (1976). Therefore, It is ordered that the petition for writ of habeas corpus is denied.

It is further ordered that the clerk of the appellate court shall process the petition for writ of habeas corpus without payment of the filing fee.

DATED: Honolulu, Hawai # i, April 6, 2022. /s/ Paula A. Nakayama /s/ Sabrina S. McKenna /s/ Michael D. Wilson /s/ Todd W. Eddins /s/ Jeannette H. Castagnetti Electronically Filed Supreme Court SCPW-22-0000223 06-APR-2022 10:12 AM Dkt. 15 ODDP
Editorial Note on Part 868
Editorial Note: Nomenclature changes to part 868 appear at 73 FR 35341, June 23, 2008.

§ 868.5540 Rigid laryngoscope. ( a ) *Identification.* A rigid laryngoscope is a device used to examine and visualize a patient's upper airway and aid placement of a tracheal tube.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 868.9
[47 FR 41107, Sept. 17, 1982, as amended at 61 FR 1120, Jan. 16, 1996; 66 FR 38795, July 25, 2001]
<TABLE> <S> <C>

<ARTICLE> 5
<RESTATED> 
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1996
<PERIOD-START>                             JUL-01-1996
<PERIOD-END>                               SEP-30-1996
<CASH>                                           1,014
<SECURITIES>                                    13,315
<RECEIVABLES>                                    4,823
<ALLOWANCES>                                        65
<INVENTORY>                                          0
<CURRENT-ASSETS>                                20,514
<PP&E>                                           2,356
<DEPRECIATION>                                     574
<TOTAL-ASSETS>                                  23,041
<CURRENT-LIABILITIES>                            3,599
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        17,771
<OTHER-SE>                                       1,197
<TOTAL-LIABILITY-AND-EQUITY>                    23,041
<SALES>                                          7,116
<TOTAL-REVENUES>                                 7,116
<CGS>                                                0
<TOTAL-COSTS>                                    3,990
<OTHER-EXPENSES>                                 2,636
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                  22
<INCOME-PRETAX>                                    683
<INCOME-TAX>                                       168
<INCOME-CONTINUING>                                515
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                       515
<EPS-PRIMARY>                                     0.03
<EPS-DILUTED>                                     0.03
        

</TABLE>
# C_2014212EN.01001601.xml

| 7.7.2014 | EN | Official Journal of the European Union | C 212/16 |
| --- | --- | --- | --- |

7.7.2014

EN

Official Journal of the European Union

C 212/16

---

Request for a preliminary ruling from the Bundesgerichtshof (Germany) lodged on 14 April 2014 — Criminal proceedings against G

(Case C-181/14)

2014/C 212/17

Language of the case: German

Referring court

Referring court

Bundesgerichtshof

Party to the main proceedings

Party to the main proceedings

G

Question referred

Question referred

Is Article 1(2)(b) of Directive 2001/83/EC (1) of 6 November 2001, as amended by Directive 2004/27/EC (2) of 31 March 2004, to be interpreted as meaning that substances or combinations of substances, within the meaning of that provision, which merely modify — that is, do not restore or correct — human physiological functions are to be regarded as medicinal products only if they are of therapeutic benefit or at any rate bring about a modification of bodily functions along positive lines? Consequently, do substances or combinations of substances which are consumed solely for their — intoxication-inducing — psychoactive effects, and in the process also have an effect which at least poses a risk to health, fall under the definition of ‘medicinal product’ contained in the directive?

1

2

---

(1)  Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use (OJ 2001 L 311, p. 67).

1

(2)  Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending Directive 2001/83/EC (OJ 2004 L 136, p. 34).

2

---
# C_2014431EN.01002701.xml

| 1.12.2014 | EN | Official Journal of the European Union | C 431/27 |
| --- | --- | --- | --- |

1.12.2014

EN

Official Journal of the European Union

C 431/27

---

Order of the President of the General Court of 4 September 2014 — Erbslöh Aluminium v Commission

(Case T-298/14 R)

((Application for interim measures - State aid - National support for the generation of renewable electricity - Commission decision to open the State aid formal investigation procedure - Application for suspension of operation of a measure - Prima facie case))

(2014/C 431/47)

Language of the case: German

Parties

Parties

Applicant: Erbslöh Aluminium GmbH (Velbert, Germany) (represented by: T. Volz and B. Wißmann, lawyers)

Applicant:

Defendant: European Commission (represented by: T. Maxian Rusche and R. Sauer, Agents)

Defendant:

Re:

Re:

Application to suspend the legal effects of the decision by which the Commission opened the State aid formal investigation procedure concerning the German law on renewable energy.

Operative part of the order

Operative part of the order

| 1. | The application for interim measures is dismissed. |
| --- | --- |

1.

The application for interim measures is dismissed.

| 2. | The costs are reserved. |
| --- | --- |

2.

The costs are reserved.

---
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          FEB-28-1997
<PERIOD-END>                               AUG-31-1996
<CASH>                                          15,304
<SECURITIES>                                         0
<RECEIVABLES>                                    4,501
<ALLOWANCES>                                         0
<INVENTORY>                                    231,879
<CURRENT-ASSETS>                                     0
<PP&E>                                          10,828
<DEPRECIATION>                                   3,428
<TOTAL-ASSETS>                                 273,373
<CURRENT-LIABILITIES>                           23,907
<BONDS>                                        181,178
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                         1,500
<OTHER-SE>                                      64,241
<TOTAL-LIABILITY-AND-EQUITY>                   273,373
<SALES>                                        109,051
<TOTAL-REVENUES>                               110,292
<CGS>                                           90,432
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                17,329
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                  2,531
<INCOME-TAX>                                       138
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     2,393
<EPS-PRIMARY>                                      .16
<EPS-DILUTED>                                        0
        

</TABLE>
# C_2015046EN.01005202.xml

| 9.2.2015 | EN | Official Journal of the European Union | C 46/52 |
| --- | --- | --- | --- |

9.2.2015

EN

Official Journal of the European Union

C 46/52

---

Judgment of the General Court of 12 December 2014 — Heidrick & Struggles International v OHIM (THE LEADERSHIP COMPANY)

(Case T-43/14) (1)

1

((Community trade mark - Application for Community word mark THE LEADERSHIP COMPANY - Absolute grounds for refusal - Descriptiveness - Lack of distinctive character - Article 7(1)(b) and (c) of Regulation (EC) No 207/2009))

(2015/C 046/67)

Language of the case: English

Parties

Parties

Applicant: Heidrick & Struggles International Inc. (Chicago, Illinois, United States) (represented by: A. Norris, Barrister-at-Law)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (represented by: I. Harrington, acting as Agent)

Defendant:

Re:

Re:

Action brought against the decision of the Second Board of Appeal of OHIM of 10 October 2013 (Case R 338/2013-2) concerning an application for registration of the word sign THE LEADERSHIP COMPANY as a Community trade mark.

Operative part of the judgment

Operative part of the judgment

| 1) | The action is dismissed. |
| --- | --- |

1)

The action is dismissed.

| 2) | Heidrick & Struggles International Inc. is ordered to pay the costs. |
| --- | --- |

2)

Heidrick & Struggles International Inc. is ordered to pay the costs.

---

(1)  OJ C 129, 28.4.2014.

1

---
<PAGE>   1


                                                                  EXHIBIT 21.1


                              HARBINGER CORPORATION
                              LIST OF SUBSIDIARIES




                Harbinger NV
                Harbinger GmbH
                Harbinger Holdings BV
                Harbinger Computer Centrum, BV
                Harbinger Data Communications, BV
                Harbinger de Mexico, S de R.L. de C.V.
                Harbinger International s.r.l.
                Harbinger Corporation
                Acquion, Inc.
                Harbinger Corporation (Delaware)
                Harbinger Holdings, Inc.
                Harbinger SA (France)
                Harbinger Canada Corp.
                Prime Factors, Inc.
                Harbinger U.K.
§ 803.11 What form should I use to submit reports of individual adverse events and where do I obtain these forms? ( a ) If you are a manufacturer or importer, you must submit reports of individual adverse events to FDA in an electronic format in accordance with § 803.12(a) and § 803.20, unless granted an exemption under § 803.19.
( b ) Importer reports submitted to device manufacturers may be in paper format or an electronic format that includes all required data fields to ensure that the manufacturer has all required information.
( c ) If you are a user facility, you must submit reports of individual adverse events in accordance with § 803.12(b) and § 803.20.
( d ) Form FDA 3500A is available on the internet at *https://www.accessdata.fda.gov/scripts/medwatch/index.cfm .*
[79 FR 8846, Feb. 14, 2014, as amended at 80 FR 10587, Feb. 27, 2015; 85 FR 18441, Apr. 2, 2020]
<PAGE>   1
                                                               EXHIBIT 10.3.1


     RECOGNITION AND RETENTION PLAN
      FOR OFFICERS AND EMPLOYEES OF
       TAPPAN ZEE FINANCIAL, INC.

       (Adopted on March 25, 1996
     Effective as of July 11, 1996)


                AMENDMENT


1.   Article V - Effective as of July 11, 1996, the first sentence of section
5.4(a) shall be amended and restated to read in its entirety as follows:

                  Any cash dividends or distributions declared and paid with
                  respect to Shares in the Trust Fund that are, as of the record
                  date for such dividend, allocated to an Eligible Employee in
                  connection with an Award shall be held in the Trust Fund and
                  distributed to such Eligible Employee (with any earnings
                  attributable thereto) at the same time as the related Shares.


2.   Article V - Effective as of July 11, 1996, sections 5.7(a)(ii) and (iii)
shall be amended to read as follows:

                           (ii)    no individual may be granted Awards under the
                  Plan covering in excess of Sixteen Thousand Two Hundred
                  (16,200) Shares;

                           (iii)   each Award granted under the Plan shall 
                  become vested and distributable as follows:

3    Article VII - Effective as of July 11, 1996, section 7.3 shall be amended 
by adding the following new subsection "(c)" which shall read in its entirety as
follows:

                           (c)     Nothing in this section 7.3 shall be deemed 
                  to change the otherwise applicable vesting schedule for any
                  Eligible Employee.


                                   Page 1 of 1
§ 582.5260 Copper gluconate. ( a ) *Product.* Copper gluconate.
( b ) *Tolerance.* This substance is generally recognized as safe for use at a level not exceeding 0.005 percent in accordance with good manufacturing or feeding practice.
Editorial Note on Part 170
Editorial Note: Nomenclature changes to part 170 appear at 66 FR 56035, Nov. 6, 2001, and 69 FR 13717, Mar. 24, 2004.

§ 170.285 Disposition of pending GRAS affirmation petitions. Because the procedure to submit a GRAS notice is replacing the former process to submit a GRAS affirmation petition, the following will happen to a filed GRAS affirmation petition that is pending on October 17, 2016. ( a ) On October 17, 2016, we will close the docket for any GRAS affirmation petition that is still pending as of October 17, 2016.
( b ) Any person who submitted a GRAS affirmation petition described in this section may submit a GRAS notice as described in this subpart and request that we incorporate the GRAS affirmation petition as described in § 170.215.
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1373 Hemoglobin A1c test system. ( a ) *Identification.* A hemoglobin A1c test system is a device used to measure the percentage concentration of hemoglobin A1c in blood. Measurement of hemoglobin A1c is used as an aid in the diagnosis of diabetes mellitus and as an aid in the identification of patients at risk for developing diabetes mellitus.
( b ) *Classification.* Class II (special controls). The special controls for this device are: ( 1 ) The device must have initial and annual standardization verification by a certifying glycohemoglobin standardization organization deemed acceptable by FDA.
( 2 ) The premarket notification submission must include performance testing to evaluate precision, accuracy, linearity, and interference, including the following: ( i ) Performance testing of device precision must, at a minimum, use blood samples with concentrations near 5.0 percent, 6.5 percent, 8.0 percent, and 12 percent hemoglobin A1c. This testing must evaluate precision over a minimum of 20 days using at least three lots of the device and three instruments, as applicable.
( ii ) Performance testing of device accuracy must include a minimum of 120 blood samples that span the measuring interval of the device and compare results of the new device to results of a standardized test method. Results must demonstrate little or no bias versus the standardized method.
( iii ) Total error of the new device must be evaluated using single measurements by the new device compared to results of the standardized test method, and this evaluation must demonstrate a total error less than or equal to 6 percent.
( iv ) Performance testing must demonstrate that there is little to no interference from common hemoglobin variants, including Hemoglobin C, Hemoglobin D, Hemoglobin E, Hemoglobin A2, and Hemoglobin S.
( 3 ) When assay interference from Hemoglobin F or interference with other hemoglobin variants with low frequency in the population is observed, a warning statement must be placed in a black box and must appear in all labeling material for these devices describing the interference and any affected populations.
[79 FR 50551, Aug. 25, 2014]
```

[Federal Register Volume 79, Number 36 (Monday, February 24, 2014)]
[Notices]
[Page 10224]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-03598]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

[Dockets DOT-OST-2013-0105 and DOT-OST-2013-0106; Notice of Order to 
Show Cause (Order 2014-2-11)]

Applications of Western Global Airlines, LLC for Certificate 
Authority

AGENCY: Department of Transportation.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Department of Transportation is directing all interested 
persons to show cause why it should not issue orders finding Western 
Global Airlines, LLC fit, willing, and able, and awarding it 
certificates of public convenience and necessity authorizing it to 
engage in interstate and foreign charter air transportation of property 
and mail.

DATES: Persons wishing to file objections should do so no later than 
February 19, 2014.

ADDRESSES: Objections and answers to objections should be filed in 
Dockets DOT-OST-2013-0105 and DOT-OST-2013-0106 and addressed to the 
Department of Transportation, Docket Operations, 1200 New Jersey Avenue 
SE., West Building Ground Floor, Room W12-140, Washington, DC and 
should be served upon the parties listed in Attachment A to the order.

FOR FURTHER INFORMATION CONTACT: Catherine O'Toole, Air Carrier Fitness 
Division, (X-56, Office W86-469), U.S. Department of Transportation, 
1200 New Jersey Avenue SE., Washington, DC 20590, (202) 366-9721.

    Dated: February 11, 2014.
Susan L. Kurland,
Assistant Secretary for Aviation and International Affairs.
[FR Doc. 2014-03598 Filed 2-21-14; 8:45 am]
BILLING CODE P
```
Home | Member Login | Events Calendar | Help

Search AGA

Home > Knowledge Center > Energy Industry Analyses & Statistics > Energy Studies > Non-AGA

 Studies

Print This | Email to a Friend

About AGA Member Center Events Pubs/Software Our Issues Newsroom Knowledge Center

Gas Technology Institute – Fuel Switching Study

The American Gas Association (AGA) and the American Public Gas Association (APGA) commissioned the Gas Technology Institute

 (GTI) to conduct a study to evaluate the potential impact of fuel switching if new minimum efficiency standards for natural gas furnaces

 were to require condensing equipment in the replacement and new construction markets.

The objective of the research summarized in this report and accompanying spreadsheet was to develop and publish information on fuel

 switching behavior related to residential heating and water heating systems in new construction and replacement markets at national,

 regional, and state levels. The technical information is intended for use in evaluating the impact of fuel switching on the technical

 feasibility and economic justification for increasing federal minimum efficiency requirements from non-condensing furnace efficiency

 levels to condensing furnace efficiency levels.

Survey Observations

Survey Instrument

Survey Results

Contact: 

Rick Murphy, Managing Director of Sustainable Growth | 202-824-7301 | rmurphy@aga.org

Site Map | Privacy Policy | Terms and Conditions

©2014 American Gas Association

400 North Capitol Street, NW | Washington, DC 20001
§ 211.184 Component, drug product container, closure, and labeling records. These records shall include the following: ( a ) The identity and quantity of each shipment of each lot of components, drug product containers, closures, and labeling; the name of the supplier; the supplier's lot number(s) if known; the receiving code as specified in § 211.80; and the date of receipt. The name and location of the prime manufacturer, if different from the supplier, shall be listed if known.
( b ) The results of any test or examination performed (including those performed as required by § 211.82(a), § 211.84(d), or § 211.122(a)) and the conclusions derived therefrom.
( c ) An individual inventory record of each component, drug product container, and closure and, for each component, a reconciliation of the use of each lot of such component. The inventory record shall contain sufficient information to allow determination of any batch or lot of drug product associated with the use of each component, drug product container, and closure.
( d ) Documentation of the examination and review of labels and labeling for conformity with established specifications in accord with §§ 211.122(c) and 211.130(c).
( e ) The disposition of rejected components, drug product containers, closure, and labeling.
#### § 82.1254 D&C Orange No. 4.

The color additive D&C Orange No. 4 shall conform in identity and specifications to the requirements of § 74.1254(a)(1) and (b) of this chapter. D&C Orange No. 4 is restricted to use in externally applied drugs and cosmetics.

[42 FR 52396, Sept. 30, 1977]
§ 803.22 What are the circumstances in which I am not required to file a report? ( a ) If you become aware of information from multiple sources regarding the same patient and same reportable event, you may submit one medical device report.
( b ) You are not required to submit a medical device report if: ( 1 ) You are a user facility, importer, or manufacturer, and you determine that the information received is erroneous in that a device-related adverse event did not occur. You must retain documentation of these reports in your MDR files for the time periods specified in § 803.18.
( 2 ) You are a manufacturer or importer and you did not manufacture or import the device about which you have adverse event information. When you receive reportable event information in error, you must forward this information to us with a cover letter explaining that you did not manufacture or import the device in question.